Log in to save to my catalogue

Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TC...

Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TC...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3990335

Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT

About this item

Full title

Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT

Publisher

London: BMJ Publishing Group LTD

Journal title

Journal for immunotherapy of cancer, 2013-11, Vol.1 (S1), p.P30-P30, Article P30

Language

English

Formats

Publication information

Publisher

London: BMJ Publishing Group LTD

More information

Scope and Contents

Contents

We report on a 26 patient phase I/II clinical trial (NCT01352286) to investigate the safety, feasibility and anti-tumor activity of T cells engineered to express an affinity-enhanced TCR that recognizes the NY-ESO-1/LAGE-1 peptide complex HLA-A*0201-SLLMWITQC. Patients with high risk or relapsed, NYESO-1 and/or LAGE-1 positive multiple myeloma (MM)...

Alternative Titles

Full title

Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3990335

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3990335

Other Identifiers

ISSN

2051-1426

E-ISSN

2051-1426

DOI

10.1186/2051-1426-1-S1-P30

How to access this item